Akebia Therapeutics (AKBA) Stock Forecast, Price Target & Predictions
AKBA Stock Forecast
Akebia Therapeutics stock forecast is as follows: an average price target of $6.50 (represents a 238.54% upside from AKBA’s last price of $1.92) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AKBA Price Target
AKBA Analyst Ratings
Buy
Akebia Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Mar 28, 2024 | Ed Arce | H.C. Wainwright | $6.00 | $1.98 | 203.03% | 212.50% |
Mar 03, 2022 | Serge Belanger | Needham | $7.00 | $2.65 | 164.15% | 264.58% |
10
Akebia Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $6.00 |
Last Closing Price | $1.92 | $1.92 | $1.92 |
Upside/Downside | -100.00% | -100.00% | 212.50% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Mar 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
May 31, 2023 | Seaport Global | - | Sector Weight | Downgrade |
May 31, 2023 | Piper Sandler | - | Overweight | Upgrade |
Mar 03, 2022 | Needham | Buy | Buy | Hold |
Apr 29, 2021 | Mizuho Securities | Buy | Buy | Hold |
10
Akebia Therapeutics Financial Forecast
Akebia Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $42.05M | $56.38M | $40.13M | $55.18M | $48.96M | $126.76M | $61.70M | $59.60M | $48.76M | $52.91M | $52.30M | $56.70M | $59.99M | $90.14M | $88.48M | $69.56M | $91.98M | $100.80M | $72.67M | $45.93M | $20.86M |
Avg Forecast | $57.03M | $47.43M | $38.53M | $36.10M | $49.57M | $44.50M | $49.80M | $46.09M | $55.39M | $48.18M | $59.10M | $46.68M | $47.40M | $48.88M | $53.03M | $44.27M | $51.77M | $49.62M | $52.31M | $42.32M | $51.10M | $84.90M | $74.18M | $77.48M | $93.15M | $99.38M | $91.12M | $81.02M | $56.42M | $7.09M |
High Forecast | $65.11M | $54.15M | $43.99M | $46.14M | $50.12M | $50.80M | $56.86M | $46.09M | $56.06M | $55.01M | $67.47M | $53.30M | $54.11M | $48.88M | $53.03M | $44.27M | $51.77M | $49.62M | $52.31M | $42.32M | $51.10M | $84.90M | $74.18M | $77.48M | $93.15M | $99.38M | $91.12M | $81.02M | $67.70M | $8.51M |
Low Forecast | $45.84M | $38.13M | $30.97M | $26.05M | $49.01M | $35.77M | $40.03M | $46.09M | $54.73M | $38.73M | $47.51M | $37.53M | $38.10M | $48.88M | $53.03M | $44.27M | $51.77M | $49.62M | $52.31M | $42.32M | $51.10M | $84.90M | $74.18M | $77.48M | $93.15M | $99.38M | $91.12M | $81.02M | $45.13M | $5.67M |
# Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | 0.95% | 0.86% | 1.16% | 1.00% | 2.39% | 1.39% | 1.15% | 0.98% | 1.01% | 1.24% | 1.11% | 0.71% | 1.22% | 1.14% | 0.75% | 0.93% | 1.11% | 0.90% | 0.81% | 2.94% |
Forecast
Akebia Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
EBITDA | - | - | - | - | - | - | - | - | - | $-3.50M | $-8.66M | $-24.73M | $-3.91M | $-37.40M | $58.27M | $-47.93M | $-66.31M | $-44.98M | $-68.57M | $-55.25M | $-81.59M | $-51.06M | $-163.82M | $-49.15M | $-87.34M | $-45.90M | $-48.84M | $-64.77M | $-22.14M | $-43.97M |
Avg Forecast | $-34.62M | $-28.79M | $-23.39M | $-21.91M | $-30.08M | $-27.01M | $-30.23M | $-46.00M | $-33.62M | $-29.24M | $-35.87M | $-41.82M | $-47.96M | $-29.67M | $-32.19M | $-38.01M | $-31.42M | $-30.12M | $-31.75M | $-27.24M | $-31.02M | $-51.53M | $-45.03M | $-63.49M | $-56.54M | $-60.31M | $-55.30M | $-32.49M | $-27.55M | $-42.13M |
High Forecast | $-27.83M | $-23.14M | $-18.80M | $-15.81M | $-29.75M | $-21.71M | $-24.30M | $-36.80M | $-33.22M | $-23.51M | $-28.83M | $-33.45M | $-38.37M | $-29.67M | $-32.19M | $-30.41M | $-31.42M | $-30.12M | $-31.75M | $-21.80M | $-31.02M | $-51.53M | $-45.03M | $-50.79M | $-56.54M | $-60.31M | $-55.30M | $-25.99M | $-22.04M | $-33.70M |
Low Forecast | $-39.52M | $-32.87M | $-26.70M | $-28.01M | $-30.42M | $-30.84M | $-34.51M | $-55.20M | $-34.03M | $-33.39M | $-40.95M | $-50.18M | $-57.55M | $-29.67M | $-32.19M | $-45.62M | $-31.42M | $-30.12M | $-31.75M | $-32.69M | $-31.02M | $-51.53M | $-45.03M | $-76.19M | $-56.54M | $-60.31M | $-55.30M | $-38.99M | $-33.06M | $-50.56M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.12% | 0.24% | 0.59% | 0.08% | 1.26% | -1.81% | 1.26% | 2.11% | 1.49% | 2.16% | 2.03% | 2.63% | 0.99% | 3.64% | 0.77% | 1.54% | 0.76% | 0.88% | 1.99% | 0.80% | 1.04% |
Forecast
Akebia Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
Net Income | - | - | - | - | - | - | - | - | - | $-14.49M | $-11.17M | $-16.74M | $-8.76M | $-55.74M | $29.28M | $-66.35M | $-65.59M | $-59.54M | $-83.04M | $-69.58M | $-87.00M | $-59.96M | $-175.75M | $-60.75M | $-94.48M | $-54.59M | $-58.17M | $-72.42M | $-23.42M | $-44.54M |
Avg Forecast | $-5.61M | $-11.22M | $-18.23M | $-16.83M | $-12.62M | $-13.32M | $-15.20M | $-59.90M | $-8.06M | $-17.88M | $-5.26M | $-54.46M | $-52.63M | $-35.65M | $-67.80M | $-49.51M | $-63.96M | $-67.11M | $-71.11M | $-34.31M | $-83.28M | $-35.39M | $-100.66M | $-75.44M | $-99.09M | $-89.27M | $-67.37M | $-35.85M | $-27.78M | $-42.26M |
High Forecast | $-4.18M | $-8.36M | $-13.58M | $2.40M | $-4.21M | $-9.92M | $-11.32M | $-47.92M | $-4.84M | $-13.32M | $-3.92M | $-43.57M | $-42.11M | $-35.65M | $-67.80M | $-39.61M | $-63.96M | $-67.11M | $-71.11M | $-27.45M | $-83.28M | $-35.39M | $-100.66M | $-60.36M | $-99.09M | $-89.27M | $-67.37M | $-28.68M | $-22.23M | $-33.81M |
Low Forecast | $-6.64M | $-13.28M | $-21.59M | $-33.66M | $-16.83M | $-15.78M | $-18.00M | $-71.88M | $-9.68M | $-21.17M | $-6.23M | $-65.35M | $-63.16M | $-35.65M | $-67.80M | $-59.41M | $-63.96M | $-67.11M | $-71.11M | $-41.17M | $-83.28M | $-35.39M | $-100.66M | $-90.53M | $-99.09M | $-89.27M | $-67.37M | $-43.02M | $-33.34M | $-50.71M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.81% | 2.12% | 0.31% | 0.17% | 1.56% | -0.43% | 1.34% | 1.03% | 0.89% | 1.17% | 2.03% | 1.04% | 1.69% | 1.75% | 0.81% | 0.95% | 0.61% | 0.86% | 2.02% | 0.84% | 1.05% |
Forecast
Akebia Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
SG&A | - | - | - | - | - | - | - | - | - | $22.71M | $27.04M | $25.22M | $31.50M | $31.66M | $33.70M | $45.02M | $45.85M | $47.23M | $42.55M | $42.02M | $41.29M | $40.88M | $36.53M | $38.66M | $45.89M | $35.11M | $36.96M | $35.03M | $9.02M | $5.79M |
Avg Forecast | $31.93M | $26.56M | $21.57M | $20.21M | $27.75M | $24.91M | $27.88M | $43.20M | $31.01M | $26.98M | $33.09M | $39.27M | $24.98M | $27.37M | $29.69M | $35.70M | $28.98M | $27.78M | $29.29M | $20.72M | $28.61M | $47.53M | $41.53M | $48.01M | $52.15M | $55.64M | $51.02M | $17.34M | $10.71M | $5.49M |
High Forecast | $36.46M | $30.32M | $24.63M | $25.83M | $28.06M | $28.44M | $31.83M | $51.84M | $31.39M | $30.80M | $37.78M | $47.13M | $29.98M | $27.37M | $29.69M | $42.84M | $28.98M | $27.78M | $29.29M | $24.87M | $28.61M | $47.53M | $41.53M | $57.61M | $52.15M | $55.64M | $51.02M | $20.81M | $12.85M | $6.59M |
Low Forecast | $25.67M | $21.35M | $17.34M | $14.58M | $27.44M | $20.03M | $22.41M | $34.56M | $30.64M | $21.68M | $26.60M | $31.42M | $19.98M | $27.37M | $29.69M | $28.56M | $28.98M | $27.78M | $29.29M | $16.58M | $28.61M | $47.53M | $41.53M | $38.41M | $52.15M | $55.64M | $51.02M | $13.87M | $8.57M | $4.39M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.84% | 0.82% | 0.64% | 1.26% | 1.16% | 1.14% | 1.26% | 1.58% | 1.70% | 1.45% | 2.03% | 1.44% | 0.86% | 0.88% | 0.81% | 0.88% | 0.63% | 0.72% | 2.02% | 0.84% | 1.05% |
Forecast
Akebia Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
EPS | - | - | - | - | - | - | - | - | - | $-0.08 | $-0.06 | $-0.09 | $-0.05 | $-0.30 | $0.16 | $-0.37 | $-0.37 | $-0.34 | $-0.51 | $-0.45 | $-0.60 | $-0.42 | $-1.28 | $-0.47 | $-0.79 | $-0.46 | $-0.49 | $-0.62 | $-0.48 | $-1.15 |
Avg Forecast | $-0.03 | $-0.05 | $-0.09 | $-0.08 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.04 | $-0.09 | $-0.03 | $-0.14 | $-0.18 | $-0.17 | $-0.32 | $-0.29 | $-0.30 | $-0.32 | $-0.34 | $-0.37 | $-0.40 | $-0.17 | $-0.48 | $-0.62 | $-0.47 | $-0.43 | $-0.32 | $-0.40 | $-0.70 | $-0.37 |
High Forecast | $-0.02 | $-0.04 | $-0.06 | $0.01 | $-0.02 | $-0.05 | $-0.05 | $-0.05 | $-0.02 | $-0.06 | $-0.02 | $-0.11 | $-0.14 | $-0.17 | $-0.32 | $-0.29 | $-0.30 | $-0.32 | $-0.34 | $-0.37 | $-0.40 | $-0.17 | $-0.48 | $-0.62 | $-0.47 | $-0.43 | $-0.32 | $-0.40 | $-0.56 | $-0.30 |
Low Forecast | $-0.03 | $-0.06 | $-0.10 | $-0.16 | $-0.08 | $-0.07 | $-0.09 | $-0.09 | $-0.05 | $-0.10 | $-0.03 | $-0.17 | $-0.22 | $-0.17 | $-0.32 | $-0.29 | $-0.30 | $-0.32 | $-0.34 | $-0.37 | $-0.40 | $-0.17 | $-0.48 | $-0.62 | $-0.47 | $-0.43 | $-0.32 | $-0.40 | $-0.84 | $-0.44 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | 2.39% | 0.62% | 0.26% | 1.76% | -0.49% | 1.29% | 1.21% | 1.06% | 1.50% | 1.22% | 1.51% | 2.49% | 2.67% | 0.76% | 1.67% | 1.08% | 1.53% | 1.55% | 0.69% | 3.11% |
Forecast
Akebia Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | $0.65 | $70.00 | 10669.23% | Buy |
ELEV | Elevation Oncology | $0.62 | $9.00 | 1351.61% | Buy |
XFOR | X4 Pharmaceuticals | $0.28 | $3.67 | 1210.71% | Buy |
AKBA | Akebia Therapeutics | $1.92 | $6.50 | 238.54% | Buy |
MCRB | Seres Therapeutics | $0.59 | $1.25 | 111.86% | Buy |
CDTX | Cidara Therapeutics | $13.90 | $24.00 | 72.66% | Buy |